Blaze at the massive El Segundo facility, a key fuel supplier for Southern California, raises concerns over potential price impacts.
Shares of the recently-listed marine fuel provider hit all-time lows on massive volume as the market reacts to unspecified executive shifts.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Settlement with Dr. Reddy's Laboratories shields key drugs NEXLETOL and NEXLIZET from generic competition until 2040, boosting investor confidence.
Governor Newsom's signature on AB30 is expected to expand the ethanol market by over 600 million gallons annually.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
The networking specialist saw trading volume spike more than 50 times its daily average following the announcement.